Literature DB >> 19896418

Pseudoviral immunity - a novel concept for lupus.

Hans-Joachim Anders1.   

Abstract

Systemic lupus erythematosus (SLE or lupus) is a polygenic syndrome of immunity against nuclear autoantigens. Recent data from several fields now suggest 'pseudoviral' immunity as a novel disease concept. Known lupus risk factors commonly compromise those mechanisms that protect chromatin and ribonucleoprotein particles from activating viral nucleic acid sensors. This process activates antigen-presenting cells and induces type I interferons. These central mediators of antiviral immunity have similar proinflammatory roles in lupus, explaining overlapping clinical manifestations, immunopathology and ultrastructural abnormalities in systemic viral infection and lupus. Structurally, chromatin and ribonucleoprotein particles resemble viral particles and have a similar potency to trigger antigen-specific B- and T-cell responses. Therefore, self nucleic acid-driven 'pseudoviral' immunity is evolving as another concept in understanding the pathogenesis of lupus and may offer novel targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896418     DOI: 10.1016/j.molmed.2009.10.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  19 in total

Review 1.  Immunopathology of lupus nephritis.

Authors:  Hans-Joachim Anders; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

2.  IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production.

Authors:  Maciej Lech; Marc Weidenbusch; Onkar P Kulkarni; Mi Ryu; Murthy Narayana Darisipudi; Heni Eka Susanti; Hans-Willi Mittruecker; Tak W Mak; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2011-07-08       Impact factor: 10.121

3.  Mdm2 promotes systemic lupus erythematosus and lupus nephritis.

Authors:  Ramanjaneyulu Allam; Sufyan G Sayyed; Onkar P Kulkarni; Julia Lichtnekert; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2011-09-23       Impact factor: 10.121

Review 4.  A novel pathogenetic concept-antiviral immunity in lupus nephritis.

Authors:  Adriana Migliorini; Hans-Joachim Anders
Journal:  Nat Rev Nephrol       Date:  2012-01-17       Impact factor: 28.314

Review 5.  Mizoribine in the treatment of pediatric-onset glomerular disease.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Taddatsu Imaizumi
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

Review 6.  Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.

Authors:  Hiroshi Tanaka; Kensuke Joh; Tadaatsu Imaizumi
Journal:  Clin Exp Nephrol       Date:  2017-03-03       Impact factor: 2.801

7.  Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1 in human mesangial cells.

Authors:  Tadaatsu Imaizumi; Tomomi Aizawa; Chihiro Segawa; Michiko Shimada; Kazushi Tsuruga; Shogo Kawaguchi; Tomoh Matsumiya; Hidemi Yoshida; Kensuke Joh; Hiroshi Tanaka
Journal:  Clin Exp Nephrol       Date:  2014-12-04       Impact factor: 2.801

8.  New and emerging treatment approaches to lupus.

Authors:  Marion Haubitz
Journal:  Biologics       Date:  2010-09-13

Review 9.  The pathogenesis of lupus nephritis.

Authors:  Maciej Lech; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2013-08-08       Impact factor: 10.121

10.  Tumor necrosis factor-α synergistically enhances polyinosinic-polycytidylic acid-induced toll-like receptor 3 signaling in cultured normal human mesangial cells: possible involvement in the pathogenesis of lupus nephritis.

Authors:  Tadaatsu Imaizumi; Tomomi Aizawa; Ryo Hayakari; Fei Xing; Pengfei Meng; Kazushi Tsuruga; Tomoh Matsumiya; Hidemi Yoshida; Liang Wang; Tetsuya Tatsuta; Hiroshi Tanaka
Journal:  Clin Exp Nephrol       Date:  2014-03-14       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.